Trial Profile

A Phase 1b/2, Open-Label, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics, and Efficacy of SM88 in Patients With Prostate Cancer

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 06 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Racemetyrosine (Primary) ; Methoxsalen; Phenytoin; Sirolimus
Indications Prostate cancer
Focus Adverse reactions
Sponsors Tyme Technologies

Most Recent Events

15 Sep 2020 According to a Tyme Technologies Media Release, final results from this trial were published in the peer-reviewed journal Investigational New Drugs 2020.
15 Sep 2020 Final results presented in the Tyme Technologies Media Release.
13 Sep 2020 Results assessing safety and potential clinical benefit of SM-88, published in the Investigational New Drugs.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com